Esophageal cancer marker and use thereof

Abstract

The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.

1 . An antibody or a fragment or a functional equivalent thereof, the antibody having positions 33 to 61 of SEQ ID NO: 2; positions 339 to 358 and/or positions 388 to 421 of SEQ ID NO: 2; or positions 430 to 530 of SEQ ID NO: 2 as an epitope. 
     
     
         2 . The antibody or a fragment or a functional equivalent thereof according to  claim 1 , wherein the antibody is an antibody selected from monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, multifunctional antibody, bispecific or oligospecific antibody, single chain antibody, scFV, diabody, sc(Fv)2 (single chain (Fv)2), and scFv-Fc. 
     
     
         3 . A method for identifying esophageal cancer using a detection agent, wherein the detection agent comprises a substance that binds to Glypican-1 or an expression product thereof, wherein the detection agent is labeled, and wherein the detection agent is an antibody or a fragment or a functional equivalent thereof, the antibody having positions 33 to 61 of SEQ ID NO: 2; positions 339 to 358 and/or positions 388 to 421 of SEQ ID NO: 2; or positions 430 to 530 of SEQ ID NO: 2 as an epitope. 
     
     
         4 . The method according to  claim 3 , wherein the esophageal cancer comprises those in lymph node metastasis sites, squamous cell carcinoma, and/or adenocarcinoma. 
     
     
         5 . A method for treatment of esophageal cancer in a subject, comprising administering an effective amount of a Glypican-1 suppressant to the subject in need thereof, wherein the Glypican-1 suppressant is an antibody or a fragment or a functional equivalent thereof, the antibody having positions 33 to 61 of SEQ ID NO: 2; and/or positions 388 to 421 of SEQ ID NO: 2; or positions 430 to 530 of SEQ ID NO: 2 as an epitope. 
     
     
         6 . The method according to  claim 5 , wherein the esophageal cancer is Glypican-1 positive. 
     
     
         7 . The method according to  claim 5 , wherein the esophageal cancer comprises those in lymph node metastasis sites, squamous cell carcinoma, and/or adenocarcinoma. 
     
     
         8 . The method according to  claim 5 , wherein the esophageal cancer comprises squamous cell carcinoma. 
     
     
         9 . The method according to  claim 5 , wherein the subject has been judged as developing Glypican-1 positive esophageal cancer. 
     
     
         10 . The method according to  claim 5 , wherein the antibody is an antibody selected from monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, human antibody, multifunctional antibody, bispecific or oligospecific antibody, single chain antibody, scFV, diabody, sc(Fv)2 (single chain (Fv)2), and scFv-Fc.